Tactile Systems Technology enters the second half of 2026 with the strongest operating momentum in its public-company history, and the investment case now rests on whether a single product-line reset can hold the company to its full-year plan. The second quarter beat on almost every axis: revenue grew nine percent, gross margin expanded by a point, net income more than doubled, and adjusted EBITDA, the non-GAAP earnings measure management uses for planning, jumped nearly fifty percent. Top line landed at roughly $86 million and net income at roughly $8 million, both the best quarters in the company's history. The scale of that improvement separates a compounding business from a mature one. The engine was the lymphedema franchise, which grew twelve percent on the back of the Nimbl pump platform and a disciplined sales force, while the respiratory airway-clearance line slipped seven percent on a temporary inventory pullback tied to the launch of the next-generation AffloVest system.
The balance sheet is a quiet source of optionality: the company ended the quarter with cash and no debt drawn on the revolver, and a repurchase program that still had room to buy back shares.
The counterargument is that the respiratory dip is a small preview of a bigger transition. AffloVest is a single product in a DME channel that management is deliberately restocking after a generation change, and the company spent the first half buying LymphaTech's 3D body-measurement platform and paying $3 million for exclusive rights to MyoSleeve in the VA and DoD channels. Those are bets that the lymphedema care continuum extends beyond compression pumps. The one thing that would flip a positive read is evidence that the AffloVest inventory pullback extends into the second half and drags full-year revenue below the $360 million floor, or that the LymphaTech and MyoSleeve investments fail to show up in order flow by the end of the year. As it stands, the market is pricing a clean, profitable, low-multiple medtech compounder, and the filings so far support that label.